Jonathan Symonds is Director at Rubius Therapeutics, Inc. (RUBY). They have made 1 open-market trade across 1 company since 2018, most recently 2018-07-20.
CIK 0001693550
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $575K since 2018, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| RUBY | 25,000 | $4K |
Shares reported on the most recent Form 4, priced at the 2018-07-23 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RUBY | BUY | 2018-07-20 | 2018-07-23 | $23.00 | $575K | -22.8% | -9.4% | -36.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.